General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Under consideration for negotiation
Manufacturer:
Knight Therapeutics Inc.
Indication:
For the treatment of plaque psoriasis after the failure of a vitamin D analogue or a medium- or high-potency topical corticosteroid
Last updated July 21, 2026
Status:
Active negotiation
Manufacturer:
AstraZeneca Canada Inc.
Indication:
As an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery
Last updated July 21, 2026
Status:
Active negotiation
Manufacturer:
Samsung Bioepis Co., Ltd.
Indication:
Multiple Indications
Last updated July 16, 2026
Status:
Under consideration for negotiation
Manufacturer:
AstraZeneca Canada Inc.
Indication:
In addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus
Last updated July 13, 2026
Status:
Negotiations were not pursued
Manufacturer:
AstraZeneca Canada Inc.
Indication:
In combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by Imfinzi as monotherapy after surgery, is indicated for the treatment of resectable stage II, IIIA, or IIIB (T3-4 N2) non–small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
Last updated July 13, 2026
Status:
Active negotiation
Manufacturer:
Argenx Canada Inc.
Indication:
Chronic inflammatory demyelinating polyneuropathy
Last updated July 13, 2026
Pombiliti with Opfolda (cipaglucosidase alfa with miglustat)
Status:
Concluded with an LOI
Manufacturer:
Amicus Therapeutics Canada Inc.
Indication:
Pompe disease
Last updated July 8, 2026
Status:
Concluded with an LOI
Manufacturer:
Fresenius Kabi Canada Ltd.
Indication:
Reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors; treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity; and treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate
Last updated July 7, 2026
Status:
Concluded with an LOI
Manufacturer:
Fresenius Kabi Canada Ltd.
Indication:
Treatment of postmenopausal women with osteoporosis at high risk for fracture; treatment to increase bone mass in men with osteoporosis at high risk for fracture; treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture; treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture
Last updated July 7, 2026
Status:
Concluded with an LOI
Manufacturer:
Knight Therapeutics Inc.
Indication:
Treatment of opioid-induced constipation (OIC) in adult patients with cancer and non-cancer pain who have had an inadequate response to laxative(s).
Last updated July 7, 2026